share_log

Credit Suisse Maintains Outperform on Candel Therapeutics, Lowers Price Target to $7

Benzinga ·  Mar 31, 2023 20:57

Credit Suisse analyst Judah Frommer maintains Candel Therapeutics (NASDAQ:CADL) with a Outperform and lowers the price target from $8 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment